Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL905297 | 1.00 | ALDH1A1 (0.36) | ALDH1A1L3MBTL1GLANPSR1MAPT | |
| SCHEMBL31178079 | 1.00 | ALDH1A1 (0.36) | ALDH1A1L3MBTL1GLANPSR1MAPT | |
| SCHEMBL14216723 | 0.82 | ALDH1A1 (0.36) | ALDH1A1L3MBTL1GLANPSR1MAPT | |
| SCHEMBL15440894 | 0.79 | ALDH1A1 (0.34) | ALDH1A1L3MBTL1GLANPSR1 | |
| SCHEMBL11301100 | 0.79 | L3MBTL1 (0.34) | ALDH1A1L3MBTL1GLANPSR1 | |
| SCHEMBL3679801 | 0.79 | L3MBTL1 (0.34) | ALDH1A1L3MBTL1GLANPSR1 | |
| SCHEMBL5318288 | 0.79 | ALDH1A1 (0.34) | ALDH1A1L3MBTL1GLANPSR1 | |
| SCHEMBL30834973 | 0.78 | ALDH1A1 (0.33) | ALDH1A1L3MBTL1MAPT | |
| SCHEMBL1604416 | 0.77 | GRM2 (0.31) | — | |
| SCHEMBL31178073 | 0.77 | GRM2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2995615-A1 | CYCLOPROPYL-FUSED PYRROLIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND THEIR PHARMACEUTICAL USE | AstraZeneca AB (SE) | 2016-03-16 | — | — | EP | disclosed |
| EP-2272825-B1 | Protected amino hydroxy adamantane carboxylic acid and process for its preparation | ASTRAZENECA AB (SE) | 2015-11-04 | — | — | EP | disclosed |
| EP-1559710-B1 | Dipeptidyl peptidase IV inhibitors based on cyclopropyl-fused pyrrolidine, process for their preparation and their use | BRISTOL MYERS SQUIBB CO (US) | 2014-02-26 | — | — | EP | disclosed |
| US-RE44186-E1 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-30 | — | — | US | disclosed |
| EP-2272825-A2 | N-Protected amino hydroxy adamantane carboxylic acid and process for its preparation | Bristol-Myers Squibb Company (US) | 2011-01-12 | — | — | EP | disclosed |
| EP-1261586-B1 | CYCLOPROPYL-FUSED PYRROLIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV, PROCESSES FOR THEIR PREPARATION, AND THEIR USE | BRISTOL MYERS SQUIBB CO (US) | 2008-05-21 | — | — | EP | disclosed |
| EP-1559710-A2 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV, process for their preparation and their use | Bristol-Myers Squibb Company (US) | 2005-08-03 | — | — | EP | disclosed |
| US-6395767-B2 | ANTIDIABETIC AGENTS; SAXAGLIPTIN | BRISTOL-MYERS SQUIBB COMPANY | 2002-05-28 | — | — | US | disclosed |
| US-20020019411-A1 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019411-A1 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method | DPP4, DPP3, DPP7 | ALDH1A1 1033/4885L3MBTL1 2140/4885GLA 1872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.